KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Return on Sales (2016 - 2025)

Arbutus Biopharma's Return on Sales history spans 13 years, with the latest figure at 14.61% for Q3 2025.

  • For Q3 2025, Return on Sales rose 12.0% year-over-year to 14.61%; the TTM value through Sep 2025 reached 2.89%, up 848.0%, while the annual FY2024 figure was 11.33%, 731.0% down from the prior year.
  • Return on Sales for Q3 2025 was 14.61% at Arbutus Biopharma, down from 0.23% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.23% in Q2 2025 and bottomed at 14.73% in Q3 2024.
  • The 5-year median for Return on Sales is 6.65% (2021), against an average of 6.88%.
  • The largest annual shift saw Return on Sales crashed -1041bps in 2024 before it soared 1170bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 6.65% in 2021, then skyrocketed by 47bps to 3.51% in 2022, then tumbled by -156bps to 9.0% in 2023, then rose by 12bps to 7.94% in 2024, then crashed by -84bps to 14.61% in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Return on Sales are 14.61% (Q3 2025), 0.23% (Q2 2025), and 13.91% (Q1 2025).